ERCC1 expression in diffuse large b-cell lymphoma patients treated with a cisplatin-based regimen : a brief communication

There is growing interest in defining biomarkers that could predict response to different chemotherapeutic agents. Excision repair cross complement 1 (ERCC1) enzyme has been shown to predict benefit of cisplatin in different types of cancer. As cisplatin-based regimens are frequently used in the sal...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of Egyptian National Cancer Institute 2007-09, Vol.19 (3), p.176-177
Hauptverfasser:	Martinellli, Giovanni, Steffanoni, Sarah, Raviele, Paola R., Pruneri, Giancarlo, Azim, Hatim A., Peccatori, Fedro A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Lymphomas الأورام
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!